United Therapeutics (FRA:UTH) Cyclically Adjusted PB Ratio: (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:UTH United Therapeutics Corp FRA:UTH
90 GF Score
Price €430.30
GF Value €375.81
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is United Therapeutics Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


United Therapeutics  (FRA:UTH) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


United Therapeutics Cyclically Adjusted PB Ratio Related Terms


United Therapeutics Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for United Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

United Therapeutics Cyclically Adjusted PB Ratio Chart

United Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.10 4.49 2.89 4.21 4.60

United Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.94 4.18 4.85 5.57 5.03

FRA:UTH vs VTRS, NBIX, ZTS: Cyclically Adjusted PB Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, United Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


United Therapeutics Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, United Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where United Therapeutics's Cyclically Adjusted PB Ratio falls into.


FRA:UTH
90GF Score
United Therapeutics Corp FRA:UTH
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

United Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

United Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, United Therapeutics's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=131.174/333.9520*333.9520
=131.174

Current CPI (Jun. 2026) = 333.9520.

United Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201609 38.351 241.428 53.048
201612 40.851 241.432 56.506
201703 42.861 243.801 58.710
201706 35.851 244.955 48.876
201709 40.524 246.819 54.830
201712 40.480 246.524 54.836
201803 44.354 249.554 59.354
201806 50.443 251.989 66.850
201809 53.191 252.439 70.366
201812 55.964 251.233 74.390
201903 47.146 254.202 61.937
201906 51.235 256.143 66.799
201909 56.770 256.759 73.838
201912 56.443 256.974 73.351
202003 61.069 258.115 79.012
202006 62.098 257.797 80.442
202009 63.000 260.280 80.832
202012 62.347 260.474 79.935
202103 65.452 264.877 82.521
202106 68.366 271.696 84.031
202109 73.397 274.310 89.355
202112 77.177 278.802 92.443
202203 82.881 287.504 96.271
202206 90.804 296.311 102.339
202209 102.209 296.808 115.000
202212 97.637 296.797 109.860
202303 100.978 301.836 111.722
202306 105.720 305.109 115.714
202309 114.836 307.789 124.597
202312 115.174 306.746 125.389
202403 111.814 312.332 119.554
202406 119.667 314.175 127.200
202409 122.525 315.301 129.773
202412 138.811 315.605 146.880
202503 139.808 319.799 145.995
202506 135.157 322.561 139.930
202509 130.730 324.800 134.414
202512 138.444 324.054 142.673
202603 121.491 330.213 122.867
202606 131.174 333.952 131.174

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is United Therapeutics (FRA:UTH) Overvalued in 2026?

Based on GuruFocus' analysis, United Therapeutics stock appears to be overvalued. The current stock price of €430.30 is trading 14.5% above its estimated GF Value™ of €375.81. GuruFocus considers United Therapeutics to be Modestly Overvalued.

Key valuation signals for FRA:UTH:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: €375.81 vs. price of €430.30 (14.5% above fair value)
  • GF Score™: 90/100 with 3 warning signs

No single metric tells the full story. See the FRA:UTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


United Therapeutics Business Description

Other Exchanges UTHR:USAU2TH34:Brazil
Address 1000 Spring Street, Silver Spring, MD, USA, 20910
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
90GF Score

Get the complete analysis for FRA:UTH

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€430.30
Price
€375.81
GF Value